Clinical Trial Detail

NCT ID NCT02575222
Title Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

clear cell renal cell carcinoma

Therapies

Nivolumab

Age Groups: adult

No variant requirements are available.